Biofrontera AG Shares Outstanding 2017-2021 | BFRA

Biofrontera AG shares outstanding from 2017 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Biofrontera AG Annual Shares Outstanding
(Millions of Shares)
2020 27
2019 22
2018 22
2017 19
2016 15
Biofrontera AG Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30
2021-03-31 27
2020-09-30
2020-03-31 22
2019-03-31 22
2018-09-30 8
2017-09-30 8
2017-03-31 19
2016-12-31 16
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.167B $0.036B
Biofrontera AG is a biopharmaceutical company. It engaged in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases. The company's products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions which can sometimes lead to skin cancer as well as the treatment of certain forms of basal cell carcinoma in the European Union. Biofrontera AG is based in Leverkusen, Germany.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76